Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes - Feinglos, M. N.; Saad, M. F.; Pi-Sunyer, F. X.; An, B.; Santiago, O. (Diabetic medicine, 2005)
Keywords: Adult; Aged; Biological and medical sciences; Blood Glucose - drug effects; Blood Glucose - metabolism; Body Mass Index; Body Weight - drug effects; Delayed-Action Preparations; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Diabetes. Impaired glucose tolerance; dose-response; Double-Blind Method; Drug Administration Schedule; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Female; GLP-1; Glucagon - administration & dosage; Glucagon - analogs & derivatives; Glucagon - therapeutic use; Glucagon-Like Peptide 1 - analogs & derivatives; Glycated Hemoglobin A - drug effects; Glycated Hemoglobin A - metabolism; Humans; Hypoglycemic Agents - administration & dosage; Liraglutide; Male; Medical sciences; Middle Aged; secretagogue; weight; β-cell; Endocrinopathy; Type 2 diabetes; Human; GLP-1; Peptides; Body weight; Langerhans islet; Metabolic diseases; secretagogue; weight; β-cell; Dose activity relation; Regulation(control); dose-response; β Cell; Glycemia; Liraglutide; Endocrine pancreas